152 related articles for article (PubMed ID: 16845240)
1. Repeated subileus due to angioedema during renin-angiotensin system blockade.
Tojo A; Onozato ML; Fujita T
Am J Med Sci; 2006 Jul; 332(1):36-8. PubMed ID: 16845240
[TBL] [Abstract][Full Text] [Related]
2. Renin angiotensin system blockers-associated angioedema in the Thai population: analysis from Thai National Pharmacovigilance Database.
Win TS; Chaiyakunapruk N; Suwankesawong W; Dilokthornsakul P; Nathisuwan S
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):227-35. PubMed ID: 26342120
[TBL] [Abstract][Full Text] [Related]
3. Prevention and management of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors.
Weinstein J; Girard LP; Lepage S; McKelvie RS; Tennankore K
CMAJ; 2021 Dec; 193(48):E1836-E1841. PubMed ID: 34872955
[No Abstract] [Full Text] [Related]
4. Hyperkalemia Associated with Renin-Angiotensin-Aldosterone System Inhibition in Patients with Heart Failure; Underexplored and Overrated?
Koratala A; Aboud H; Kazory A
Nephron; 2018; 138(3):220-221. PubMed ID: 29176327
[No Abstract] [Full Text] [Related]
5. Successful effect of triple blockade of renin-angiotensin-aldosterone system on massive proteinuria in a patient with chronic kidney disease.
Kuriyama S; Sugano N; Ueda H; Otsuka Y; Kanzaki G; Hosoya T
Clin Exp Nephrol; 2009 Dec; 13(6):663-6. PubMed ID: 19629623
[TBL] [Abstract][Full Text] [Related]
6. Hyperkalemia: a threat to RAAS inhibition?
Schrier RW
Nat Rev Nephrol; 2010 May; 6(5):245-6. PubMed ID: 20424624
[No Abstract] [Full Text] [Related]
7. [Angio-oedema and medication that interferes with the renin-angiotensin-aldosterone system--a systematic review].
Suhrs HE; Ibsen H
Ugeskr Laeger; 2012 Mar; 174(11):724-9. PubMed ID: 22409895
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
[TBL] [Abstract][Full Text] [Related]
9. Future drug discovery in renin-angiotensin-aldosterone system intervention.
Tamargo M; Tamargo J
Expert Opin Drug Discov; 2017 Aug; 12(8):827-848. PubMed ID: 28541811
[TBL] [Abstract][Full Text] [Related]
10. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
11. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
12. Gram-negative pneumonia among patients undergoing dialysis who were admitted to the hospital with angioedema secondary to angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists.
Sharma M; Johnson LB
Clin Infect Dis; 2008 Dec; 47(11):1494-5. PubMed ID: 18986269
[No Abstract] [Full Text] [Related]
13. Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review.
Li SM; He WB; Chen J; Cai QQ; Huang FF; Zhang K; Wang JF; Liu X; Huang H
Atherosclerosis; 2018 Feb; 269():35-41. PubMed ID: 29258005
[TBL] [Abstract][Full Text] [Related]
14. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
15. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
16. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
Ribeiro SC; Figueiredo AE; Barretti P; Pecoits-Filho R; de Moraes TP;
Am J Nephrol; 2017; 46(2):150-155. PubMed ID: 28738355
[TBL] [Abstract][Full Text] [Related]
17. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
[TBL] [Abstract][Full Text] [Related]
18. Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney.
Tylicki L; Rutkowski P; Renke M; Rutkowski B
Kidney Int; 2007 Nov; 72(9):1164-5. PubMed ID: 17943159
[No Abstract] [Full Text] [Related]
19. [Dual blockade of the renin-angiotensin system in hypertensive treatment: no].
van der Giet M
Dtsch Med Wochenschr; 2012 Nov; 137(48):2499. PubMed ID: 23168984
[No Abstract] [Full Text] [Related]
20. New potassium binders reduce the risk of hyperkalaemia in patients treated with renin-angiotensin-aldosterone system inhibitors.
Tamargo M; Tamargo J
Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):193-194. PubMed ID: 29982385
[No Abstract] [Full Text] [Related]
[Next] [New Search]
